A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

NCT03275701 ·Status: UNKNOWN ·Phase: NA

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

NCT02616783 ·Status: COMPLETED ·Phase: PHASE3

Effect of Tenofovir DF on Bone Metabolism in Children

NCT00088309 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years

NCT03405935 ·Status: COMPLETED ·Phase: PHASE3

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

NCT01902186 ·Status: TERMINATED ·Phase: PHASE4

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 ·Status: COMPLETED ·Phase: PHASE3

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers

NCT00648817 ·Status: COMPLETED ·Phase: PHASE4

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

NCT00122512 ·Status: TERMINATED ·Phase: PHASE2

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

NCT03646370 ·Status: COMPLETED

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)

NCT03549689 ·Status: WITHDRAWN ·Phase: PHASE2

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

NCT01966822 ·Status: COMPLETED ·Phase: PHASE3

Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs

NCT00016588 ·Status: COMPLETED ·Phase: NA

Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations

NCT00011089 ·Status: UNKNOWN ·Phase: NA

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

NCT00106379 ·Status: COMPLETED ·Phase: PHASE4

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

NCT01343225 ·Status: UNKNOWN ·Phase: PHASE4

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

NCT02616029 ·Status: COMPLETED ·Phase: PHASE3

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551 ·Status: COMPLETED ·Phase: PHASE3

ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment

NCT01671982 ·Status: COMPLETED ·Phase: PHASE1

Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies

NCT02209740 ·Status: COMPLETED

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850 ·Status: COMPLETED ·Phase: PHASE2

Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy

NCT00312832 ·Status: COMPLETED ·Phase: NA

Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD

NCT04311944 ·Status: UNKNOWN ·Phase: NA

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655 ·Status: COMPLETED

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT02733419 ·Status: COMPLETED ·Phase: PHASE3